[go: up one dir, main page]

AR083241A1 - Metodos y kits para el diagnostico de cancer de prostata - Google Patents

Metodos y kits para el diagnostico de cancer de prostata

Info

Publication number
AR083241A1
AR083241A1 ARP110102567A ARP110102567A AR083241A1 AR 083241 A1 AR083241 A1 AR 083241A1 AR P110102567 A ARP110102567 A AR P110102567A AR P110102567 A ARP110102567 A AR P110102567A AR 083241 A1 AR083241 A1 AR 083241A1
Authority
AR
Argentina
Prior art keywords
prostate
methods
subject
prostate cancer
kits
Prior art date
Application number
ARP110102567A
Other languages
English (en)
Inventor
Andreas Doll
Resina Marina Rigau
Robles Juan Morote
Posada Miguel Abal
Puigjaner Jaume Reventos
Original Assignee
Fundacio Inst De Recerca Hospital Uni Vall D & Rsquo Hebron Fundacio Privada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst De Recerca Hospital Uni Vall D & Rsquo Hebron Fundacio Privada filed Critical Fundacio Inst De Recerca Hospital Uni Vall D & Rsquo Hebron Fundacio Privada
Publication of AR083241A1 publication Critical patent/AR083241A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente se refiere a métodos y kits para el diagnostico de cáncer de próstata (CAP) en un sujeto, para evaluar o seguir la respuesta a una terapia en un sujeto que tiene cáncer de próstata (CAP) o para seguir la evolución del cáncer de próstata (CAP) basados en la detección de cambios en los niveles de expresión de al menos un gen seleccionado del grupo antígeno de cáncer de próstata 3 (PCA3), antígeno de membrana específico de próstata (PSMA) y receptor acoplado de proteína G específico de próstata (PSGR). La presente se refiere a si mismo a métodos para evaluar si un sujeto se tiene que someter a una biopsia de próstata, dicho sujeto tiene PSA en suero en el intervalo de 4 - 10 hg/ml.
ARP110102567A 2010-07-14 2011-07-15 Metodos y kits para el diagnostico de cancer de prostata AR083241A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10382193A EP2407554A1 (en) 2010-07-14 2010-07-14 Methods and kits for the diagnosis of prostate cancer

Publications (1)

Publication Number Publication Date
AR083241A1 true AR083241A1 (es) 2013-02-13

Family

ID=42670648

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102567A AR083241A1 (es) 2010-07-14 2011-07-15 Metodos y kits para el diagnostico de cancer de prostata

Country Status (5)

Country Link
US (1) US20130171653A1 (es)
EP (2) EP2407554A1 (es)
AR (1) AR083241A1 (es)
TW (1) TW201217785A (es)
WO (1) WO2012007546A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153441A1 (en) 2014-03-31 2015-10-08 University Of Washington Methods and systems for selectively disrupting tissue with high intensity focused ultrasound
WO2015153909A2 (en) 2014-04-02 2015-10-08 Chevillet John R High intensity focused ultrasound and methods of performing non-invasive biopsies using same
KR102384848B1 (ko) 2016-08-05 2022-04-08 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 방광암용 바이오마커로서의 케라틴 17
MX2019009027A (es) * 2017-02-13 2020-01-27 Genomic Health Inc Algoritmos y metodos para evaluar criterios de valoracion tardios en cancer de prostata.
CN108441557A (zh) * 2018-01-31 2018-08-24 广州瑞博奥生物科技有限公司 Pca3和psa基因检测试剂盒及其应用
WO2021257905A2 (en) * 2020-06-17 2021-12-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Olfactory receptors for use as targets for antigen binding molecules to detect and treat cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935860A (en) 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
WO1998024935A1 (en) 1996-12-06 1998-06-11 Urocor, Inc. Diagnosis of disease state using mrna profiles
US7008765B1 (en) 1997-04-10 2006-03-07 The Johns Hopkins University PCA3, PCA3 genes, and methods of use
EP1210110A4 (en) 1999-06-29 2003-03-19 Univ Mcgill PRION PROTEIN BINDING PROTEINS, AND USES THEREOF
AU2002245727A1 (en) * 2001-04-05 2002-10-21 The Henry M. Jackson Foundation Enhanced diagnostic potential of prostate-specific antigen expressing cells
US20050282170A1 (en) 2003-02-07 2005-12-22 Diagnocure Inc. Method to detect prostate cancer in a sample
CA2432365A1 (en) 2003-06-30 2004-12-30 Jack A. Schalken Specific method of prostate cancer detection based on pca3, and kits therefore
DE102006032394B4 (de) * 2006-03-17 2011-07-07 Technische Universität Dresden, 01069 Verfahren zur Diagnose und Differenzierung von Prostatakrebs
US20100233691A1 (en) 2007-03-30 2010-09-16 Source Precision Medicine, Inc. D/B/A Source Mdx Gene Expression Profiling for Identification, Monitoring and Treatment of Prostate Cancer
EP2288722B1 (en) * 2008-04-10 2014-11-05 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
EP2300040A4 (en) 2008-05-01 2012-06-27 Beth Israel Hospital METHOD AND COMPOSITIONS FOR IMMUNOTHERAPY IN PROSTATE CANCER

Also Published As

Publication number Publication date
EP2407554A1 (en) 2012-01-18
TW201217785A (en) 2012-05-01
EP2593561A1 (en) 2013-05-22
US20130171653A1 (en) 2013-07-04
WO2012007546A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
CU20120095A7 (es) Antagonistas de pcsk9
MX2017015260A (es) Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer.
AR083241A1 (es) Metodos y kits para el diagnostico de cancer de prostata
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
MX2013008367A (es) Firmas de esxpresion genetica de cancer de colon y metodos de uso.
MX2018010361A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
MX341517B (es) Biomarcadores de cancer pancreatico y usos de los mismos.
EA201400710A1 (ru) Способы детекции признаков заболеваний или состояний в жидкостях организма
MX368394B (es) Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
EP2611941A4 (en) GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
MX367366B (es) Composiciones y metodos para diagnosticar tumores de tiroides.
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
AR080505A1 (es) Metodos para el tratamiento de linfoma no hodkin usando lenalidomida, y bimarcadores genicos y proteicos como indicadores
MX2013003077A (es) Diagnostico de cancer de mama.
ES2570627T3 (es) Ensayo in vitro de Ezrina para el diagnóstico del cáncer colorrectal
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies

Legal Events

Date Code Title Description
FB Suspension of granting procedure